{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:09:16Z","timestamp":1788815356262,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijgc.2026.104641","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:24:56Z","timestamp":1773246296000},"page":"104641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of BRCA status on the efficacy of paclitaxel monotherapy in recurrent ovarian cancer"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1233-9850","authenticated-orcid":false,"given":"Giorgia","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4614-9261","authenticated-orcid":false,"given":"Adriana Ionelia","family":"Apostol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2586-832X","authenticated-orcid":false,"given":"Ilary","family":"Ruscito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Maria","family":"Sassu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Diella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6833-0696","authenticated-orcid":false,"given":"Fabiana","family":"Salvati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5509-4193","authenticated-orcid":false,"given":"Filippo Maria","family":"Capomacchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena Maria","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1155-3888","authenticated-orcid":false,"given":"Laura","family":"Vertechy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8965-9981","authenticated-orcid":false,"given":"Christian","family":"Marth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-335X","authenticated-orcid":false,"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7098-8956","authenticated-orcid":false,"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ijgc.2026.104641_bib1","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7035","key":"10.1016\/j.ijgc.2026.104641_bib2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104641_bib3","first-page":"1091","article-title":"Standard first-line chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the randomized phase 3 ICON7 trial","volume":"17","author":"du Bois","year":"2016","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ijgc.2026.104641_bib4","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the Aurelia open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104641_bib5","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104641_bib6","first-page":"550","article-title":"Chemotherapy for patients with platinum-resistant ovarian cancer: what is better than nothing?","volume":"7","author":"Tan","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104641_bib7","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","article-title":"Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance","volume":"68","author":"Swisher","year":"2008","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104641_bib8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4161\/cc.5.9.2726","article-title":"BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance","volume":"5","author":"Chabalier","year":"2006","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104641_bib10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104641_bib11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/cas.15185","article-title":"Efficacy and safety of standard of care with\/without bevacizumab for platinum-resistant ovarian\/fallopian tube\/peritoneal cancer previously treated with bevacizumab: the Japanese Gynecologic Oncology Group study JGOG3023","volume":"113","author":"Shoji","year":"2022","journal-title":"Cancer Sci"},{"issue":"10385","key":"10.1016\/j.ijgc.2026.104641_bib12","first-page":"281","article-title":"Mirvetuximab soravtansine vs chemotherapy in platinum-resistant ovarian cancer (MIRASOL): a phase 3 randomized trial","volume":"401","author":"Moore","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104641_bib13","first-page":"915","article-title":"Folate receptor alpha (FR\u03b1) expression in epithelial ovarian cancer: a biomarker for targeted therapy","volume":"12","author":"Berek","year":"2021","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104641_bib14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha as a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104641_bib15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104641_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.annonc.2024.10.828","article-title":"Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1\/ENGOT-ov25 trial","volume":"36","author":"Harter","year":"2025","journal-title":"Ann Oncol"},{"issue":"7540","key":"10.1016\/j.ijgc.2026.104641_bib17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104641_bib18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4161\/cc.5.9.2726","article-title":"BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance","volume":"5","author":"Chabalier-Taste","year":"2006","journal-title":"Cell Cycle."},{"key":"10.1016\/j.ijgc.2026.104641_bib19","first-page":"24","article-title":"BRCA mutations and outcome in epithelial ovarian cancer (EOC)","author":"Safra","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104641_bib20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","article-title":"Rucaparib monotherapy in recurrent ovarian carcinoma after platinum and PARP inhibitor treatment (ARIEL4): a randomized, multicentre, open-label, phase 3 trial","volume":"23","author":"Kristeleit","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104641_bib21","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/IGC.0000000000000086","article-title":"The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer","volume":"24","author":"Safra","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.104641_bib22","doi-asserted-by":"crossref","first-page":"S1697","DOI":"10.1016\/j.annonc.2025.09.049","article-title":"LBA3 Pembrolizumab vs placebo plus weekly paclitaxel \u00b1 bevacizumab in platinum-resistant recurrent ovarian cancer: results from the randomized double-blind phase III ENGOT-ov65\/KEYNOTE-B96 study","volume":"36","author":"Colombo","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104641_bib23","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/jcm8030380","article-title":"Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector T cell subsets","volume":"8","author":"Napoletano","year":"2019","journal-title":"J Clin Med"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26001726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26001726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:47:52Z","timestamp":1788814072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26001726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1048891X26001726"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104641","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of BRCA status on the efficacy of paclitaxel monotherapy in recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104641"}}